Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 106, Issue 11, Pages 1826-1832
Publisher
Springer Nature
Online
2012-05-02
DOI
10.1038/bjc.2012.175
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinicopathological Significance of microRNA-31, -143 and -145 Expression in Colorectal Cancer
- (2013) Chao-Jie Wang et al. DISEASE MARKERS
- Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours
- (2011) S Weidlich et al. BRITISH JOURNAL OF CANCER
- MicroRNA dysregulation in colorectal cancer: a clinical perspective
- (2011) Y Dong et al. BRITISH JOURNAL OF CANCER
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Restitution of Tumor Suppressor MicroRNAs Using a Systemic Nanovector Inhibits Pancreatic Cancer Growth in Mice
- (2011) D. Pramanik et al. MOLECULAR CANCER THERAPEUTICS
- miR-143 Overexpression Impairs Growth of Human Colon Carcinoma Xenografts in Mice with Induction of Apoptosis and Inhibition of Proliferation
- (2011) Pedro M. Borralho et al. PLoS One
- A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy
- (2010) W. Zhang et al. ANNALS OF ONCOLOGY
- MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer
- (2010) Kah Hoong Chang et al. BMC CANCER
- A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors
- (2010) Andrey Loboda et al. BMC Medical Genomics
- Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases
- (2010) Vlastimil Kulda et al. CANCER GENETICS AND CYTOGENETICS
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
- (2010) Alberto Bardelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- MicroRNAs and Their Therapeutic Potential for Human Diseases: MicroRNAs, miR-143 and -145, Function as Anti-oncomirs and the Application of Chemically Modified miR-143 as an Anti-cancer Drug
- (2010) Yukio Kitade et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan
- (2010) F Graziano et al. PHARMACOGENOMICS JOURNAL
- Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma
- (2010) Hiromitsu Hatakeyama et al. PLoS One
- MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer
- (2009) E K O Ng et al. BRITISH JOURNAL OF CANCER
- MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells
- (2009) Pedro M. Borralho et al. FEBS Journal
- Evaluation of High-Resolution Melting Analysis as a Diagnostic Tool to Detect the BRAF V600E Mutation in Colorectal Tumors
- (2009) Martin Pichler et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Role of miR-143 targeting KRAS in colorectal tumorigenesis
- (2009) X Chen et al. ONCOGENE
- KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- (2008) Astrid Lièvre et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Analyzing real-time PCR data by the comparative CT method
- (2008) Thomas D Schmittgen et al. Nature Protocols
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More